Enarodustat is under clinical development by Japan Tobacco and currently in Phase I for Anemia in Chronic Kidney Disease (Renal Anemia). According to GlobalData, Phase I drugs for Anemia in Chronic Kidney Disease (Renal Anemia) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Enarodustat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Enarodustat overview

Enarodustat (Enaroy)  is a potent anti-anemic agent. It is formulated as film coated tablets for oral route of administration. Enaroy is indicated for the treatment of anemia associated with chronic kidney disease (CKD).

Enarodustat (JTZ-951) is under development for the treatment of anemia associated with chronic kidney disease. 

Japan Tobacco overview

Japan Tobacco (JT Group) is a tobacco company that manufactures cigarettes. It also manufactures, markets, and sells varied pharmaceutical and processed food products such as frozen cooked rice and noodles, instant noodles, bread, and frozen bread, packaged cooked rice, bakery goods, yeast extracts and seasoning, prescription drugs, and generic drugs. The company distributes its products through supermarkets, street and train station kiosks, convenience stores, small independent retailers, and vending machines. JT Group caters to retail, industrial and commercial customers in Europe, Africa, the Middle East, Asia-Pacific, and the Americas, and other regions. The company manufactures its products in its own facilities in Japan and other countries. JT Group is headquartered in Minato-Ku, Tokyo, Japan.

For a complete picture of Enarodustat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.